PMID- 23574619
OWN - NLM
STAT- MEDLINE
DCOM- 20131210
LR  - 20130516
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 14
IP  - 9
DP  - 2013 Jun
TI  - The hidden costs of anticoagulation in hospitalized patients with non-valvular 
      atrial fibrillation.
PG  - 1119-33
LID - 10.1517/14656566.2013.789022 [doi]
AB  - INTRODUCTION: Non-valvular atrial fibrillation (NVAF) and ischemic stroke are 
      collectively associated with annual hospital costs of tens of billions of dollars 
      in the USA. Oral anticoagulant (OAC) treatment with warfarin reduces the risk of 
      stroke in patients with NVAF. Unfortunately, because of the complexity of 
      warfarin therapy and potential for adverse events (AEs), many patients who might 
      benefit go untreated or receive suboptimal therapy, increasing their stroke 
      and/or bleeding risk. AREAS COVERED: This review explores current hospital costs 
      and resource utilization for NVAF patients on warfarin therapy and the potential 
      impact of newer OACs in this area. EXPERT OPINION: Many ischemic strokes could be 
      prevented through wider use of OACs. Further, admissions due to 
      anticoagulant-associated AEs could be reduced by optimizing OAC therapy. In the 
      hospital, specialized anticoagulation services can decrease costs by improving 
      the effectiveness of warfarin management, empowering patients through education 
      and optimizing care transitions. With fewer interactions and no dose titration or 
      monitoring required, the novel OACs (NOACs) have the potential to further 
      decrease inpatient resource utilization and costs. It is important that, as data 
      become available, inpatient costs are included in cost-benefit comparisons 
      between warfarin and the NOACs.
FAU - Burnett, Allison
AU  - Burnett A
AD  - University of New Mexico Hospital, Inpatient Pharmacy Department, Albuquerque, 
      NM, USA.
FAU - Tiongson, Jay
AU  - Tiongson J
FAU - Downey, Ross
AU  - Downey R
FAU - Mahan, Charles E
AU  - Mahan CE
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130411
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/administration & dosage/economics/*therapeutic use
MH  - Atrial Fibrillation/complications/*drug therapy/economics
MH  - Cost-Benefit Analysis
MH  - Drug Monitoring/economics/methods
MH  - Hospital Costs
MH  - Humans
MH  - Stroke/economics/*prevention & control
MH  - United States
MH  - Warfarin/administration & dosage/economics/therapeutic use
EDAT- 2013/04/12 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/04/12 06:00
PHST- 2013/04/12 06:00 [entrez]
PHST- 2013/04/12 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.1517/14656566.2013.789022 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2013 Jun;14(9):1119-33. doi: 
      10.1517/14656566.2013.789022. Epub 2013 Apr 11.